Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Chronic kidney disease
•
Nephrology
Do you recommend delaying spot urine protein quantification testing until after nephrostomy tube removal in a patient with obstructive uropathy?
Answer from: at Community Practice
Yes, if the tubes are coming out. Would not want to make treatment decisions under these circumstances. Not an emergency usually.
Sign in or Register to read more
Answer from: at Academic Institution
Not necessarily. I don't think it would affect it much.
Sign in or Register to read more
26903
26910
Related Questions
Is there a role for early GLP-1 therapy for weight loss in patients with early-stage ADPKD and obesity, given the association between obesity and the risk of progression to ESKD?
What are your top takeaways from ASN 2024?
Are there instances when you recommend against a kidney biopsy in a patient with a single kidney who otherwise has indications for a biopsy, consents, and has no medical contraindications for the procedure?
Do you advise your patients with CKD to consume a set amount of fluids daily in an attempt to prevent disease progression?
How do you approach managing patients with diabetic kidney disease and proteinuria who develop hypoglycemia after initiation of a SGLT2 inhibitor?
Do you offer home administration of ESAs for your patients with anemia of chronic kidney disease?
Would you avoid a 24 hour urine collection for creatinine clearance measurement in a patient who is on fluid restriction?
Would you start an SGLT2 inhibitor in patients with diabetic kidney disease who also have a history of prior toe amputation?
Do you recommend stopping a SGLT2i indefinitely if a patient with chronic kidney disease and diabetes develops euglycemic diabetic ketoacidosis?
Do you have a preference between an ACEi and ARB when initiating therapy for a patient with diabetic kidney disease, albuminuria, and hypertension?